Tag: Cardiosense

Cardiosense Receives FDA 510(k) Clearance for the CardioTag™ Device, Paving the Way for Advanced Cardiac Function Monitoring

The CardioTag device fuses multiple sensing modalities to capture unique insights about the relationship between cardiac mechanics, electrical impulses, and blood flow – valuable inputs that can be used by AI algorithms to assess cardiac pressures and volume status  CHICAGO–July 29, 2025–Cardiosense, a medical AI company transforming cardiovascular disease management, […]

Cardiosense Launches Nationwide SEISMIC-HF II Study to Validate Its AI Algorithm for Non-Invasive Heart Failure Management

SEISMIC-HF II follows promising results from the peer-reviewed SEISMIC-HF I study, demonstrating accuracy of the Company’s non-invasive cardiac filling pressure algorithm comparable to that of FDA-approved implantable sensors CHICAGO – May 28, 2025 – Cardiosense, a medical AI company transforming cardiovascular disease management, today announced the launch of SEISMIC-HF II, […]

Results from Cardiosense’s SEISMIC-HF I Study of a Machine Learning Model to Non-Invasively Assess Cardiac Filling Pressure Presented as Late-Breaking Science at American Heart Association’s 2024 Scientific Sessions

SEISMIC-HF I enrolled a large, demographically diverse population across 15 sites Results are an important step toward enabling widespread, non-invasive hemodynamic-guided heart failure management CHICAGO, Nov. 20, 2024 /PRNewswire/ — Cardiosense, a medical AI company transforming the…

Cardiosense Presents Interim Clinical Study Data for Machine Learning Algorithm to Aid in Heart Failure Management at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 Scientific Symposium

CHICAGO, Oct. 28, 2024 /PRNewswire/ — Cardiosense, a digital health company developing heart failure management platforms for the early detection of worsening heart failure, today presented clinical data at the Cardiovascular Research Foundation’s 2024 annual Transcatheter Cardiovascular…

Cardiosense Begins Enrollment in Nationwide Heart Failure Study

CHICAGO, Sept. 26, 2023 /PRNewswire/ — Cardiosense, a digital health company developing a non-invasive monitoring platform for the early detection of heart disease, recently started enrolling patients in SEISMIC-HF I, its nationwide clinical study to refine and validate algorithms to assess intracardiac filling pressure, an early physiological marker for acute heart failure […]

Cardiosense, Inc., Completes $15.1 Million Series A Financing to Advance Artificial Intelligence Platform for Heart Disease

CHICAGO, Dec. 8, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint […]